These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17803610)

  • 1. Hydroquinone--what is its future?
    Toombs EL
    Dermatol Ther; 2007; 20(3):149-56. PubMed ID: 17803610
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy.
    Charlín R; Barcaui CB; Kac BK; Soares DB; Rabello-Fonseca R; Azulay-Abulafia L
    Int J Dermatol; 2008 Jan; 47(1):19-23. PubMed ID: 18173595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical treatments for melasma and postinflammatory hyperpigmentation.
    Lynde CB; Kraft JN; Lynde CW
    Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroquinone: myths and reality.
    Searle T; Al-Niaimi F; Ali FR
    Clin Exp Dermatol; 2021 Jun; 46(4):636-640. PubMed ID: 33159818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hyperpigmentation.
    Woolery-Lloyd H; Kammer JN
    Semin Cutan Med Surg; 2011 Sep; 30(3):171-5. PubMed ID: 21925372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous ochronosis hydroquinone induced: a report of four cases.
    Ribas J; Schettini AP; Cavalcante Mde S
    An Bras Dermatol; 2010; 85(5):699-703. PubMed ID: 21152798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
    Fabi SG; Goldman MP
    J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
    J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
    J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
    Makino ET; Mehta RC; Banga A; Jain P; Sigler ML; Sonti S
    J Drugs Dermatol; 2013 Mar; 12(3):s16-20. PubMed ID: 23545928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenous ochronosis.
    Snider RL; Thiers BH
    J Am Acad Dermatol; 1993 Apr; 28(4):662-4. PubMed ID: 8463477
    [No Abstract]   [Full Text] [Related]  

  • 12. Hydroquinone and the FDA--the debate?
    Palm MD; Toombs EL
    J Drugs Dermatol; 2007 Feb; 6(2):122. PubMed ID: 17373168
    [No Abstract]   [Full Text] [Related]  

  • 13. Exogenous ochronosis.
    Martín RF; Sánchez JL; González A; Lugo-Somolinos A; Ruiz H
    P R Health Sci J; 1992 Apr; 11(1):23-6. PubMed ID: 1603931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exogenous ochronosis and striae atrophicae following the use of bleaching creams.
    Bongiorno MR; Aricò M
    Int J Dermatol; 2005 Feb; 44(2):112-5. PubMed ID: 15689207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dermoscopy for diagnosis of exogenous ochronosis.
    Romero SA; Pereira PM; Mariano AV; Francesconi F; Francesconi VA
    An Bras Dermatol; 2011; 86(4 Suppl 1):S31-4. PubMed ID: 22068765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous ochronosis: case report and literature review.
    Martins VM; Sousa AR; Portela Nde C; Tigre CA; Gonçalves LM; Castro Filho RJ
    An Bras Dermatol; 2012; 87(4):633-6. PubMed ID: 22892783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exogenous ochronosis. An update on clinical features, causative agents and treatment options.
    Levin CY; Maibach H
    Am J Clin Dermatol; 2001; 2(4):213-7. PubMed ID: 11705248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream.
    Baliña LM; Graupe K
    Int J Dermatol; 1991 Dec; 30(12):893-5. PubMed ID: 1816137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exogenous ochronosis, a little-known side effect of hydroquinone-containing ointments].
    Menke HE; Dekker SK; Noordhoek Hegt V; Pavel S; Westerhof W
    Ned Tijdschr Geneeskd; 1992 Jan; 136(4):187-90. PubMed ID: 1736131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous ochronosis.
    Merola JF; Meehan S; Walters RF; Brown L
    Dermatol Online J; 2008 Oct; 14(10):6. PubMed ID: 19061605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.